Thermosensitive chitosan-based hydrogel: a vehicle for overcoming the limitations of nose-to-brain cell therapy.

bioactive vehicle(6) cell therapy(5) functionalized chitosan(1) mucoadhesive(3) nose-to-brain(4) thermosensitive hydrogel(2)

Journal

Acta biomaterialia
ISSN: 1878-7568
Titre abrégé: Acta Biomater
Pays: England
ID NLM: 101233144

Informations de publication

Date de publication:
06 Sep 2024
Historique:
received: 07 05 2024
revised: 31 08 2024
accepted: 03 09 2024
medline: 9 9 2024
pubmed: 9 9 2024
entrez: 8 9 2024
Statut: aheadofprint

Résumé

Cell therapy is a promising strategy for treating neurological pathologies but requires invasive methods to bypass the blood-brain barrier restrictions. The nose-to-brain route has been presented as a direct and less invasive alternative to access the brain. The primary limitations of this route are low retention in the olfactory epithelium and poor cell survival in the harsh conditions of the nasal cavity. Thus, using chitosan-based hydrogel as a vehicle is proposed in this work to overcome the limitations of nose-to-brain cell administration. The hydrogel's design was driven to achieve gelification in response to body temperature and a mucosa-interacting chemical structure biocompatible with cells. The hydrogel showed a <30 min gelation time at 37°C and >95% biocompatibility with 2D and 3D cultures of mesenchymal stromal cells. Additionally, the viability, stability, and migration capacity of oligodendrocyte precursor cells (OPCs) within the hydrogel were maintained in vitro for up to 72 hours. After the intranasal administration of the OPCs-containing hydrogel, histological analysis showed the presence of viable cells in the nasal cavity for up to 72 hours post-administration in healthy athymic mice. These results demonstrate the hydrogel's capacity to increase the residence time in the nasal cavity while providing the cells with a favorable environment for their viability. This study presents for the first time the use of thermosensitive hydrogels in nose-to-brain cell therapy, opening the possibility of increasing the delivery efficiency in future approaches in translational medicine. STATEMENT OF SIGNIFICANCE: : This work highlights the potential of biomaterials, specifically hydrogels, in improving the effectiveness of cell therapy administered through the nose. The nose-to-brain route has been suggested as a non-invasive way to directly access the brain. However, delivering stem cells through this route poses a challenge since their viability must be preserved and cells can be swept away by nasal mucus. Earlier attempts at intranasal cell therapy have shown low efficiency, but still hold promise to the future. The hydrogels designed for this study can provide stem cells with a biocompatible environment and adhesion to the nasal atrium, easing the successful migration of viable cells to the brain.

Identifiants

pubmed: 39245308
pii: S1742-7061(24)00510-5
doi: 10.1016/j.actbio.2024.09.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Doddy Denise Ojeda-Hernández (DD)

Laboratorio de Neurobiología, Instituto de Neurociencias. Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.

Susana Velasco-Lozano (S)

Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), CSIC-Universidad de Zaragoza, C/ Pedro Cerbuna, 12, 50009, Zaragoza, Spain; Aragonese Foundation for Research and Development (ARAID), Av. Ranillas, 1-D, 50018, Zaragoza, Spain.

José María Fraile (JM)

Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), CSIC-Universidad de Zaragoza, C/ Pedro Cerbuna, 12, 50009, Zaragoza, Spain.

Juan C Mateos-Díaz (JC)

Unidad de Biotecnología Industrial. Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco (CIATEJ), Zapopan, Mexico.

Francisco Javier Rojo-Pérez (FJ)

Centro de Tecnología Biomédica, Universidad Politécnica de Madrid, Pozuelo de Alarcón, 28223 Madrid, Spain; Departamento de Ciencia de Materiales, ETSI Caminos, Canales y Puertos, Universidad Politécnica de Madrid, 28040 Madrid, Spain; Grupo de Biomateriales y Medicina Regenerativa, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.

María Soledad Benito-Martín (MS)

Laboratorio de Neurobiología, Instituto de Neurociencias. Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.

Belén Selma-Calvo (B)

Laboratorio de Neurobiología, Instituto de Neurociencias. Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.

Sarah de la Fuente-Martín (S)

Laboratorio de Neurobiología, Instituto de Neurociencias. Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.

Marina García-Martín (M)

Laboratorio de Neurobiología, Instituto de Neurociencias. Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.

María Teresa Larriba-González (MT)

Laboratorio de Neurobiología, Instituto de Neurociencias. Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.

Mercedes Azucena Hernández-Sapiéns (MA)

Unidad de Evaluación Preclínica, Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco (CIATEJ), Guadalajara, Mexico.

Alejandro A Canales-Aguirre (AA)

Unidad de Evaluación Preclínica, Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco (CIATEJ), Guadalajara, Mexico.

Jordi A Matias-Guiu (JA)

Laboratorio de Neurobiología, Instituto de Neurociencias. Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain; Servicio de Neurología, Instituto de Neurociencias. Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Universidad Complutense de Madrid, Spain.

Jorge Matias-Guiu (J)

Laboratorio de Neurobiología, Instituto de Neurociencias. Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain; Servicio de Neurología, Instituto de Neurociencias. Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Universidad Complutense de Madrid, Spain.

Ulises Gomez-Pinedo (U)

Laboratorio de Neurobiología, Instituto de Neurociencias. Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain. Electronic address: u.gomez.pinedo@gmail.com.

Classifications MeSH